IVA
Inventiva S.A. NASDAQ Listed Jul 10, 2020$3.41
-2.57%
vs $3.50
Mkt Cap $637.0M
52w Low $2.98
10.3% of range
52w High $7.15
50d MA $4.73
200d MA $5.22
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-2.0x
ROE
—
P/FCF
-6.3x
RSI (14)
28.50
ATR (14)
$0.18
Beta
0.95
50d MA
$4.73
200d MA
$5.22
Avg Volume
841.4K
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
50 rue de Dijon · Daix, I0 21121 · FR
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.28 | -1.07 | -282.1% | 5.48 | -4.9% | +1.3% | -2.2% | +0.7% | +3.7% | -5.8% | — |
| Sep 25, 2025 | AMC | -0.41 | -1.89 | -361.7% | 6.01 | -2.8% | +0.7% | -3.0% | -1.4% | +2.1% | +6.6% | — |
| May 23, 2025 | AMC | -0.47 | -2.69 | -473.0% | 3.09 | +5.2% | +8.7% | -2.1% | +3.0% | +0.0% | +0.0% | — |
| Sep 25, 2024 | AMC | -0.56 | -1.01 | -81.1% | 2.17 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% | — |
| Mar 27, 2024 | AMC | -0.40 | -1.25 | -211.7% | 3.82 | -1.8% | -5.2% | +1.7% | -1.4% | +0.3% | +0.5% | — |
| Sep 28, 2023 | AMC | -1.27 | -1.43 | -13.1% | 4.26 | +0.7% | -1.4% | -4.0% | +2.0% | +3.4% | -3.5% | — |
| Mar 29, 2023 | AMC | -0.57 | -0.64 | -11.9% | 3.76 | -1.6% | -7.7% | +4.9% | -2.2% | -4.5% | +1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $4.06 | $3.99 | -1.7% | +3.0% | -1.2% | -6.1% | +10.8% | -6.0% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.36 | $5.00 | -6.7% | +3.2% | -17.7% | +1.3% | +7.6% | +10.3% |
| Sep 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.87 | $5.69 | -3.1% | -1.4% | +2.1% | +6.6% | +3.7% | -4.4% |
| Sep 2 | Guggenheim | Maintains | Buy → Buy | — | $6.19 | $5.49 | -11.3% | -15.0% | +9.7% | -2.9% | -0.5% | -3.6% |
| Apr 4 | Guggenheim | Maintains | Buy → Buy | — | $3.02 | $3.46 | +14.6% | +1.7% | +1.0% | -1.9% | +4.6% | -3.1% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $3.15 | +7.1% | +5.4% | -2.6% | +1.7% | +1.0% | -1.9% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.04 | $3.01 | -1.0% | -4.3% | +1.0% | +0.0% | +5.4% | -2.6% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.30 | $2.49 | +8.3% | +5.2% | +0.4% | +4.5% | -3.1% | +3.3% |
| Nov 22 | Stifel | Maintains | Buy → Buy | — | $2.66 | $2.56 | -3.8% | -1.5% | +1.9% | -1.1% | +1.5% | -1.1% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.67 | $2.62 | -1.9% | -2.6% | -6.9% | +0.0% | +8.7% | +3.8% |
| Sep 26 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.17 | $2.10 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% |
| Sep 26 | Stifel | Maintains | Buy → Buy | — | $2.17 | $2.10 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.10 | -3.2% | -17.5% | +2.8% | +1.6% | -4.8% | +5.6% |
| Apr 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.78 | $3.77 | -0.3% | +2.1% | -0.3% | +1.0% | -4.9% | -4.1% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.95 | +9.1% | +1.7% | -1.4% | +0.3% | +0.5% | +3.3% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.45 | $3.51 | +1.7% | +10.1% | -0.5% | +1.6% | -1.0% | -0.5% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.78 | +4.4% | +6.9% | -0.5% | +3.6% | -1.0% | +1.5% |
| Feb 16 | Stifel | Maintains | Buy → Buy | — | $3.94 | $3.34 | -15.2% | -16.0% | +1.5% | -2.7% | +4.0% | +0.6% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.19 | -0.2% | +3.1% | +4.4% | -2.4% | +2.7% | -0.9% |
| Sep 21 | Roth MKM | Maintains | Buy → Buy | — | $3.83 | $4.15 | +8.4% | +9.4% | +4.5% | -1.6% | +3.0% | -6.3% |
| Sep 1 | Guggenheim | Maintains | Buy → Buy | — | $3.70 | $3.77 | +1.9% | -1.1% | +7.4% | -8.1% | +6.9% | -8.3% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $3.86 | +0.0% | +4.4% | +1.5% | -0.2% | -5.6% | +2.1% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.58 | $4.51 | -1.5% | +6.6% | -2.5% | -2.1% | -4.5% | -4.5% |
| May 31 | Roth MKM | Maintains | Buy → Buy | — | $3.03 | $3.16 | +4.3% | +30.2% | -2.4% | +3.4% | -1.9% | -1.9% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.82 | $2.90 | +2.8% | +0.0% | +7.4% | +30.2% | -2.4% | +3.4% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.47 | $3.47 | +0.0% | +4.9% | -2.2% | -4.5% | +1.9% | -4.2% |
| Mar 17 | Stifel | Maintains | Buy → Buy | — | $4.43 | $4.68 | +5.7% | +2.9% | -6.3% | -6.3% | +1.2% | +3.1% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.90 | $3.98 | +2.1% | +0.5% | -2.8% | -3.1% | +1.3% | +2.5% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.34 | $13.75 | +3.1% | +3.1% | -0.4% | +0.5% | -2.0% | -3.0% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.20 | $13.12 | -0.6% | +1.9% | +0.0% | -0.2% | -0.3% | +1.0% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.93 | $14.50 | +4.1% | +3.0% | +1.7% | -1.8% | -1.0% | -3.8% |
| Sep 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.00 | $13.98 | -0.1% | -0.5% | +3.0% | +1.7% | -1.8% | -1.0% |
| Mar 8 | Societe Generale | Downgrade | Buy → Sell | — | $14.20 | $13.60 | -4.2% | -3.5% | -1.1% | -6.1% | +0.8% | +3.9% |
| Mar 7 | Societe Generale | Downgrade | Buy → Sell | — | — | — | — | — | — | — | — | — |
| Aug 5 | Roth Capital | Maintains | Buy → Buy | — | $10.50 | $10.90 | +3.8% | +1.6% | +6.5% | +4.5% | +2.8% | -2.0% |
| Aug 4 | Stifel | Maintains | Buy → Buy | — | $10.24 | $10.60 | +3.5% | +2.5% | +1.6% | +6.5% | +4.5% | +2.8% |
| Aug 4 | Guggenheim | Maintains | Buy → Buy | — | $10.24 | $10.60 | +3.5% | +2.5% | +1.6% | +6.5% | +4.5% | +2.8% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Samsara Biocapital, Llc | 5,194,805 | $24M | New | Dec 2025 |
| 2 | Millennium Management | 2,987,613 | $17M | Added | Mar 2026 |
| 3 | Trails Edge Capital Partners, Lp | 2,657,997 | $15M | — | Mar 2026 |
| 4 | Franklin Resources Inc | 2,461,565 | $14M | Reduced | Mar 2026 |
| 5 | Ubs Group Ag | 2,318,693 | $13M | Reduced | Mar 2026 |
| 6 | Adar1 Capital Management, Llc | 2,174,398 | $12M | New | Mar 2026 |
| 7 | Andera Partners | 1,818,181 | $10M | — | Mar 2026 |
| 8 | Yu Fan | 1,500,000 | $8M | New | Mar 2026 |
| 9 | Rtw Investments, Lp | 1,298,702 | $7M | — | Mar 2026 |
| 10 | Point72 Asset Management | 956,221 | $5M | New | Mar 2026 |
| 11 | Morgan Stanley | 1,015,402 | $5M | Added | Dec 2025 |
| 12 | Ally Bridge Group (Ny) Llc | 745,300 | $4M | New | Mar 2026 |
| 13 | Propel Bio Management, Llc | 724,678 | $4M | Reduced | Mar 2026 |
| 14 | Marshall Wace, Llp | 654,211 | $4M | Added | Mar 2026 |
| 15 | Artisan Partners Limited Partnership | 323,006 | $2M | New | Mar 2026 |
| 16 | Two Sigma Investments, Lp | 226,406 | $1M | Added | Mar 2026 |
| 17 | Russell Investments Group, Ltd. | 205,639 | $1M | New | Mar 2026 |
| 18 | Persistent Asset Partners Ltd | 128,099 | $711K | Reduced | Mar 2026 |
| 19 | Quadrature Capital Ltd | 84,323 | $468K | Added | Mar 2026 |
| 20 | Commonwealth Equity Services, Llc | 77,561 | $361K | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Franklin Biotechnology Discovery Fund | 908,000 | $6M | Jan 2026 |
| 2 | Artisan International Small-Mid Fund | 195,745 | $1M | Mar 2026 |
| 3 | U.S. Small Cap Equity Fund | 35,424 | $218K | Jan 2026 |
| 4 | U.S. Small Cap Equity Fund | 9,220 | $51K | Mar 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 4,695 | $30K | Feb 2026 |
Valuation
Market Cap
$637.0M
Enterprise Value
$562.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
—
P/S
46.56x
P/FCF
-6.29x
EV/EBITDA
—
Shares Out
186.8M
Financials (TTM)
Revenue
$13.7M
Net Income
-$537.0M
EBITDA
-$410.1M
Free Cash Flow
-$101.2M
Op Cash Flow
-$101.0M
EPS Basic
$-1.82
EPS Diluted
$-5.44
EPS Forward
$-0.68
Gross Margin
78.8%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$248.9M
Total Liab.
$277.9M
Total Equity
-$29.0M
Cash
$99.3M
LT Debt
$24.8M
Book Value/Sh
$-0.16
Debt/Equity
-2.05x
Current Ratio
3.15
Quick Ratio
3.15
Returns & Growth
ROE
—
ROA
—
ROIC
-64.4%
Rev Growth YoY
-51.3%
EPS Growth YoY
+48.6%
Price Returns
2W
-11.2%
1M
-3.9%
3M
-24.0%
6M
+16.0%
12M
+45.4%
Technicals
52W High
$7.15
52W Low
$2.98
50d MA
$4.73
200d MA
$5.22
RSI (14)
28.50
ATR (14)
$0.18
Beta
0.95
Avg Volume
841K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.80
High
$24.00
Low
$12.00
Median
$13.00
Data updated apr 26, 2026 11:06am
· Source: financialmodelingprep.com